Whales with a lot of money to spend have taken a noticeably bullish stance on Moderna.Looking at options history for Moderna (NASDAQ:MRNA) we detected 22 trades.If we consider the specifics of each trade, it is accurate to state that 45% of the investors opened trades with bullish expectations and 36% with bearish.From the overall spotted trades, 4 are puts, for a total amount of $774,679 and 18, calls, for a total amount of $1,215,014.What's The Price Target?Taking into account the Volume and Open Interest ...

Skip to main content Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost February 23, 20268:15 PM UTCUpdated ago By Ahmed Aboulenein U.S. Food and Drug Administration Commissioner Marty Makary speaks during a press conference at the Department of Health and Human Services in Washington, D.C., U.S., November 10, 2025.... Purchase Licensing Rights, opens new tab Read ...

Group 1: Laffont's Investment Strategy - Billionaire Philippe Laffont, founder of Coatue Management, oversees $39 billion in 13F securities, primarily investing in technology stocks, with Taiwan Semiconductor Manufacturing as his largest holding at over 6.5% of his portfolio [1] - In the fourth quarter of the previous year, Laffont sold his entire position in CoreWeave, which had been a significant AI stock with triple-digit revenue growth [2][9] - Laffont's recent investment in Moderna, a biotech stock that has struggled but saw a nearly 50% increase in January, indicates a shift towards potential growth opportunities [3][12] Group 2: CoreWeave and Moderna - CoreWeave, which Laffont sold, had made up more than 2.2% of his portfolio and had seen an 80% increase since its IPO [8][9] - Moderna, which Laffont purchased 200,000 shares of, represents a very small position at 0.01% of his portfolio, but the company is focusing on long-term success through cost-cutting and expanding its vaccine offerings [10][11] - Moderna's stock has lost over 70% in the past three years, but its pipeline includes candidates in late-stage development, suggesting potential for recovery and growth in the future [10][14]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _ to _ Commission File Number: 001-38753 Moderna, Inc. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation or Organi ...

Key Takeaways Moderna shares climbed 6% after the FDA agreed to review its mRNA-1010 flu vaccine filing.FDA reversed last week's refusal; decision on mRNA-1010 is due by Aug. 5, 2026.mRNA-1010 seeks full nod for 50-64 and accelerated approval for 65, launch eyed for 2026/2027.Shares of Moderna (MRNA) rose 6% on Wednesday after the company announced that the FDA agreed to review its regulatory filing seeking approval for its seasonal influenza vaccine, mRNA-1010. A final decision is expected by Aug. 5, 2026. ...

CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / February 19, 2026 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences: TD Cowen 46th Annual Healthcare Conference, on Tuesday, March 3rd at 1:50pm ET Barclays 28th Annual Global Healthcare Conference, on Tuesday, March 10th at 9:30am ET A live webcast of each of these presentations will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.co ...

The stock’s movement comes after the U.S. Food and Drug Administration (FDA) notified Moderna that its biologics license application for mRNA-1010 will proceed to review, adding pressure as broader markets experienced mixed trading.Following a Type A meeting, the FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of August 5 for mRNA-1010, which is aimed at adults aged 50 and older.Pending review and FDA approval, mRNA-1010 would be available for U.S. adults 50 years of age and older, inclu ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

A researcher works in the lab at the Moderna Inc. headquarters in Cambridge, Massachusetts, US, on Tuesday, March 26, 2024.Moderna said on Wednesday the Food and Drug Administration has agreed to review its experimental mRNA flu shot, reversing the agency's earlier decision to refuse to accept the application in a move that stunned Wall Street and the medical community. The announcement clears a path forward for the vaccine, which is key to Moderna's experimental combination Covid-flu jab and the company's ...

Moderna's stock was surging after the FDA said it would review the biotech's flu-vaccine candidate, a week after it had refused to do so. ...